GLP-1 receptor agonists (such as semaglutide, liraglutide, and tirzepatide) are highly effective for weight loss, helping many individuals lose 15–20% of their body weight. However, new research highlights what happens after these medications are discontinued.
A large meta-analysis found that patients regain about 60% of their lost weight within one year of stopping treatment. Over time, weight regain tends to slow and plateau, with individuals maintaining approximately 25% of their original weight loss long term.
For example, someone who loses 20 kg may regain about 15 kg but still remain 5 kg below their starting weight.
Why does weight regain happen?
These medications work by reducing appetite and increasing fullness. When they are stopped, that effect is removed—essentially “taking the foot off the brake,” which can lead to increased hunger and weight regain. In addition, many users of GLP-1 medications lose muscle, and this results in a slower metabolic rate.
Why do many people stop treatment?
About half of patients discontinue GLP-1 medications within the first year. Common reasons include:
- Side effects (nausea, fatigue, dizziness)
- High out-of-pocket costs when not covered by insurance
Is all the weight regained the same?
It’s still unclear whether regained weight is mostly fat or includes muscle. This is important, as regaining more fat than muscle could negatively impact overall health.
Are there any lasting benefits?
Encouragingly, some weight loss is often maintained. This may be due to:
- Improved eating habits developed during treatment
- Possible long-term metabolic or hormonal changes
What can help prevent regain?
Experts suggest:
- Gradual tapering of medication rather than abrupt stopping
- Ongoing lifestyle support (nutrition, physical activity) – with an emphasis on resistance exercise for increasing muscle mass
- Individualized long-term weight management plans
Bottom line:
GLP-1 medications are powerful tools, but they are not a short-term fix. Patients should be counseled that long-term strategies are essential to maintain weight loss after stopping therapy.
References:
Brodmerkel, Anke. “Quarter of Weight Loss Persists after Stopping GLP-1 Drugs.” Medscape, 26 Mar. 2026,
